Literature DB >> 1289271

Recurrence of superficial bladder tumours after transurethral resection.

H Fuse1, T Sakai, H Kimura, T Katayama.   

Abstract

From 1979 to January 1990, 48 patients with newly diagnosed superficial bladder tumours were treated by transurethral resection (TUR) at Toyama Medical and Pharmaceutical University Hospital. The relationship between tumour recurrence and the stage, grade, number, or size of the tumours was investigated. The 1-, 2-, 3-, 4- and 5-year non-recurrence rates were 72%, 63%, 47%, 40%, and 40%, respectively. Non-recurrence rate for pTa tumours was significantly higher than that for pT1 tumours (p < 0.05). There was no relationship between tumour grade and recurrence. The rate of recurrence of multiple tumours was higher than that of single ones. There was no difference in non-recurrence rate between tumours smaller than 1 cm and those of 1 cm or larger. Non-recurrence rate in the instillation therapy group was significantly higher than in the non-instillation group (p < 0.05). It was concluded that patients with multiple or high-stage tumours have the risk of a high rate of recurrence and that intravesical chemotherapy is effective in preventing local recurrence in some patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289271     DOI: 10.1007/bf02551297

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  16 in total

1.  Factors affecting survival in primary superficial bladder cancer.

Authors:  J Flamm; L Havelec
Journal:  Eur Urol       Date:  1990       Impact factor: 20.096

2.  A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.

Authors:  R C Flanigan; M F Ellison; K M Butler; L G Gomella; J W McRoberts
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

3.  Clinical application of 2,5-DI-O-acetyl- -D-gluca ro- (1-4) (6-3)-dilactone (SLA) to the bladder tumor, with special reference to its effect on frequency of tumor recurrences.

Authors:  T Ichikawa
Journal:  J Urol       Date:  1972-10       Impact factor: 7.450

4.  Prophylactic treatment for superficial bladder cancer following transurethral resection.

Authors:  Y Hirao; E Okajima; S Ohara; S Ozono; T Hiramatsu; K Yoshida; K Yamada; H Aoyama; M Hashimoto; S Watanabe
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  [Statistical studies on the recurrence rate in superficial bladder tumor].

Authors:  K Matsuoka; S Ueda; Y Ooyabu; Y Fujii; S Noda; K Eto
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1985-06

6.  Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.

Authors:  H Akaza; S Isaka; K Koiso; T Kotake; T Machida; A Maru; Y Matsumura; T Niijima; K Obata; H Ohe
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases.

Authors:  W Lutzeyer; H Rübben; H Dahm
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

8.  Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer.

Authors:  D Byar; C Blackard
Journal:  Urology       Date:  1977-12       Impact factor: 2.649

9.  Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone.

Authors:  C C Schulman; M Robinson; L Denis; P Smith; G Viggiano; M de Pauw; O Dalesio; R Sylvester
Journal:  Eur Urol       Date:  1982       Impact factor: 20.096

10.  Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.

Authors:  H Zincke; D C Utz; W F Taylor; R P Myers; F J Leary
Journal:  J Urol       Date:  1983-03       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.